Your browser doesn't support javascript.
loading
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
Falchook, Gerald S; Peeters, Marc; Rottey, Sylvie; Dirix, Luc Y; Obermannova, Radka; Cohen, Jonathan E; Perets, Ruth; Frommer, Ronnie Shapira; Bauer, Todd M; Wang, Judy S; Carvajal, Richard D; Sabari, Joshua; Chapman, Sonya; Zhang, Wei; Calderon, Boris; Peterson, Daniel A.
Afiliación
  • Falchook GS; Drug Development Unit, Sarah Cannon Research Institute at HealthONE, 1800 Williams St Ste 300, Denver, CO, USA. Gerald.Falchook@SarahCannon.com.
  • Peeters M; Department of Oncology, University Antwerpen, Universitair Ziekenhuis Antwerpen, Drie Eikenstraat, Edegem, Belgium.
  • Rottey S; Drug Research Unit, Universitair Ziekenhuis Gent, Corneel Heymanslaan, Ghent, Belgium.
  • Dirix LY; Department of Medical Oncology, GZA Sint Augustinus, Oosterveldlaan, Wilrijk, Belgium.
  • Obermannova R; Comprehensive Cancer Care Department - Faculty of Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
  • Cohen JE; Department of Oncology, Sharett Institute of Oncology, Hadassah Medical Center, Jerusalem, Israel.
  • Perets R; The Faculty of Medicine, The Wohl Institute for Translational Medicine, Hadassah Medical Center, Jerusalem, Israel.
  • Frommer RS; Department of Oncology, Clinical Research Institute at Rambam, Rambam Medical Center, Haifa, Israel.
  • Bauer TM; Technion - Israel Institute of Technology, Haifa, Israel.
  • Wang JS; The Ella Institute for Immuno-Oncology, Sheba Medical Center, Oncology Institute, Tel Hashomer, Ramat Gan, Israel.
  • Carvajal RD; Department of Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.
  • Sabari J; Hematologic Oncology, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA.
  • Chapman S; Department of Medicine, Division of Hematology/Oncology, Columbia University, College of Physicians and Surgeons, New York, NY, USA.
  • Zhang W; Department of Medicine,Medical Oncology, NYU Langone Health, New York, NY, USA.
  • Calderon B; Eli Lilly and Company, Windlesham, Surrey, UK.
  • Peterson DA; Eli Lilly and Company, Indianapolis, IN, USA.
Invest New Drugs ; 39(5): 1284-1297, 2021 10.
Article en En | MEDLINE | ID: mdl-33852104
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Receptores del Factor Estimulante de Colonias / Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares / Antineoplásicos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Invest New Drugs Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Receptores del Factor Estimulante de Colonias / Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares / Antineoplásicos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Invest New Drugs Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos